Image of Ovarian cancer is predominantly a disease of older, postmenopausal women with the majority (>80%) of cases being diagnosed in women over 50 years.
Bookmark Share

PRODUCT LITERATURE

Ovarian cancer is predominantly a disease of older, postmenopausal women with the majority (>80%) of cases being diagnosed in women over 50 years.

This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety ofbendamustineplusrituximab(BR) vs a standard rituximab-chemotherapy regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or rituximab plus cyclophosphamide, vincristine, and prednisone [R-CVP]) for treatmentnaive patients with indolent non-Hodgkin’s lymphoma or mantle cell lymphoma

Availability
#
Titan Center Location name is not set
Fonkomustin-001
Available
Detail Information
Series Title
-
Call Number
-
Publisher
: .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Fonkomustin
Specific Detail Info
Blood. 2014;123(19):2944-2952
Statement of Responsibility
Other version/related

No other version available

File Attachment
Comments
You must be logged in to post a comment